AbbVie is a big company that makes medicine. Some people who have lots of money think the price of this company's stock will go down soon. They are betting on it by buying something called "options". Options are like a special kind of contract that lets you buy or sell a stock at a certain price in the future. If they are right and the price goes down, they can make money. But if they are wrong, they might lose money. The people who have lots of money think AbbVie's stock will go down between $145 and $185 per share soon. Read from source...

1. The article title is misleading, as it suggests that only "smart money" is betting big in ABBV options, while the reality is that both smart and not-so-smart investors are involved. This creates a false impression of exclusivity and expertise among the investors who trade in ABBV options.
2. The article uses vague terms like "whales" and "significant investors" to describe the market participants without providing any concrete data or evidence about their identity, background, or track record. This makes it hard for the readers to evaluate the credibility of the sources and their claims.
3. The article relies heavily on options history and trading activity to determine the sentiment and price targets of the investors, while ignoring other relevant factors such as fundamentals, earnings, dividends, news, and events that may influence the stock's performance and value. This creates a narrow and incomplete picture of the market situation and potential risks and opportunities for the investors.
4. The article does not disclose any potential conflicts of interest or bias that may affect the author's objectivity and motivation for writing the article. For example, the author may be an affiliate or partner of Benzinga or have a personal stake in ABBV options. This makes it hard for the readers to trust the author's intentions and motives.
5. The article uses emotional language and phrases such as "bearish", "bullish", "price territory", and "projected price targets" to create a sense of urgency, excitement, and uncertainty among the readers. This appeals to their emotions rather than their rationality and may lead them to make impulsive and irrational decisions based on fear or greed.

Given the information provided by the article titled "Smart Money Is Betting Big In ABBV Options", I have analyzed the options history for AbbVie and derived some insights that can help you make informed decisions about your investments. Here are my suggestions, along with their respective risks:

1. Bullish recommendation: Buy AbbVie calls with a strike price between $145.0 and $185.0. This would allow you to benefit from the potential increase in the stock price over the next three months. The risk here is that the stock may not rise as expected, or may even decline, resulting in losses for your investment.

2. Bearish recommendation: Sell AbbVie puts with a strike price between $145.0 and $185.0. This would enable you to collect premium income from the options sellers while being protected by the lower strike price. The risk here is that the stock may drop below the specified level, which could trigger a buy-to-cover order and force you to purchase AbbVie shares at a higher price than the current market value.

3. Neutral recommendation: Sell AbbVie calls with a strike price between $145.0 and $185.0. This would allow you to collect premium income while capping your potential upside. The risk here is that the stock may surge higher, resulting in missed opportunities for gains. Additionally, if the stock price falls below the strike price, you could face unlimited losses.